alleen voor onderzoeksdoeleinden
Cat.nr.S1462
| Gerelateerde doelwitten | Akt mTOR GSK-3 ATM/ATR DNA-PK AMPK PDPK1 PTEN PP2A PDK |
|---|---|
| Overig PI3K Inhibitoren | GDC-0077 (Inavolisib) SAR405 Quercetin (Sophoretin) LY294002 XL147 analogue Tersolisib (STX-478) Buparlisib (BKM120) 740 Y-P (PDGFR 740Y-P) GO-203 TFA Eganelisib (IPI-549) |
| Cellijnen | Assaytype | Concentratie | Incubatietijd | Formulering | Activiteitsbeschrijving | PMID |
|---|---|---|---|---|---|---|
| human RXF393 cell | Growth inhibition assay | Inhibition of human RXF393 cell growth in a cell viability assay, IC50=0.01154 μM | ||||
| human SW982 cell | Growth inhibition assay | Inhibition of human SW982 cell growth in a cell viability assay, IC50=0.03584 μM | ||||
| human MAD-MB-468 cells | Function assay | Inhibition of PI3Kbeta in human MAD-MB-468 cells assessed as inhibition of Ser473 Akt phosphorylation by cellular potency assay, IC50=0.04 μM | ||||
| human KURAMOCHI cell | Growth inhibition assay | Inhibition of human KURAMOCHI cell growth in a cell viability assay, IC50=0.1051 μM | ||||
| human A498 cell | Growth inhibition assay | Inhibition of human A498 cell growth in a cell viability assay, IC50=0.11795 μM | ||||
| human YT cell | Growth inhibition assay | Inhibition of human YT cell growth in a cell viability assay, IC50=0.12066 μM | ||||
| human VMRC-RCZ cell | Growth inhibition assay | Inhibition of human VMRC-RCZ cell growth in a cell viability assay, IC50=0.14898 μM | ||||
| human MDA-MB-415 cell | Growth inhibition assay | Inhibition of human MDA-MB-415 cell growth in a cell viability assay, IC50=0.16732 μM | ||||
| human J82 cell | Growth inhibition assay | Inhibition of human J82 cell growth in a cell viability assay, IC50=0.47779 μM | ||||
| human SW1710 cell | Growth inhibition assay | Inhibition of human SW1710 cell growth in a cell viability assay, IC50=0.5292 μM | ||||
| human T47D cell | Growth inhibition assay | Inhibition of human T47D cell growth in a cell viability assay, IC50=0.5327 μM | ||||
| human SU-DHL-1 cell | Growth inhibition assay | Inhibition of human SU-DHL-1 cell growth in a cell viability assay, IC50=0.56813 μM | ||||
| human BT-20 cell | Growth inhibition assay | Inhibition of human BT-20 cell growth in a cell viability assay, IC50=0.59222 μM | ||||
| human OS-RC-2 cell | Growth inhibition assay | Inhibition of human OS-RC-2 cell growth in a cell viability assay, IC50=0.62388 μM | ||||
| human RPMI-6666 cell | Growth inhibition assay | Inhibition of human RPMI-6666 cell growth in a cell viability assay, IC50=0.64379 μM | ||||
| human OVCAR-3 cell | Growth inhibition assay | Inhibition of human OVCAR-3 cell growth in a cell viability assay, IC50=0.67946 μM | ||||
| human NALM-6 cell | Growth inhibition assay | Inhibition of human NALM-6 cell growth in a cell viability assay, IC50=0.70465 μM | ||||
| human RS4-11 cell | Growth inhibition assay | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50=0.73806 μM | ||||
| human SK-MES-1 cell | Growth inhibition assay | Inhibition of human SK-MES-1 cell growth in a cell viability assay, IC50=0.78967 μM | ||||
| human ES7 cell | Growth inhibition assay | Inhibition of human ES7 cell growth in a cell viability assay, IC50=0.81286 μM | ||||
| human NCI-H2342 cell | Growth inhibition assay | Inhibition of human NCI-H2342 cell growth in a cell viability assay, IC50=0.84294 μM | ||||
| human SCC-9 cell | Growth inhibition assay | Inhibition of human SCC-9 cell growth in a cell viability assay, IC50=0.8577 μM | ||||
| human EW-7 cell | Growth inhibition assay | Inhibition of human EW-7 cell growth in a cell viability assay, IC50=0.86356 μM | ||||
| human HH cell | Growth inhibition assay | Inhibition of human HH cell growth in a cell viability assay, IC50=0.96222 μM | ||||
| human A427 cell | Growth inhibition assay | Inhibition of human A427 cell growth in a cell viability assay, IC50=0.99505 μM | ||||
| human Daudi cell | Growth inhibition assay | Inhibition of human Daudi cell growth in a cell viability assay, IC50=1.06888 μM | ||||
| human P30-OHK cell | Growth inhibition assay | Inhibition of human P30-OHK cell growth in a cell viability assay, IC50=1.07138 μM | ||||
| human HGC-27 cell | Growth inhibition assay | Inhibition of human HGC-27 cell growth in a cell viability assay, IC50=1.1816 μM | ||||
| human CAMA-1 cell | Growth inhibition assay | Inhibition of human CAMA-1 cell growth in a cell viability assay, IC50=1.2001 μM | ||||
| human SK-OV-3 cell | Growth inhibition assay | Inhibition of human SK-OV-3 cell growth in a cell viability assay, IC50=1.20444 μM | ||||
| human NCI-H1048 cell | Growth inhibition assay | Inhibition of human NCI-H1048 cell growth in a cell viability assay, IC50=1.22579 μM | ||||
| human MEL-HO cell | Growth inhibition assay | Inhibition of human MEL-HO cell growth in a cell viability assay, IC50=1.24238 μM | ||||
| human NKM-1 cell | Growth inhibition assay | Inhibition of human NKM-1 cell growth in a cell viability assay, IC50=1.28636 μM | ||||
| human NCI-H650 cel | Growth inhibition assay | Inhibition of human NCI-H650 cell growth in a cell viability assay, IC50=1.30076 μM | ||||
| human HAL-01 cell | Growth inhibition assay | Inhibition of human HAL-01 cell growth in a cell viability assay, IC50=1.30175 μM | ||||
| human 786-0 cell | Growth inhibition assay | Inhibition of human 786-0 cell growth in a cell viability assay, IC50=1.31283 μM | ||||
| human GI-1 cell | Growth inhibition assay | Inhibition of human GI-1 cell growth in a cell viability assay, IC50=1.31808 μM | ||||
| human Becker cell | Growth inhibition assay | Inhibition of human Becker cell growth in a cell viability assay, IC50=1.36315 μM | ||||
| human CCF-STTG1 cell | Growth inhibition assay | Inhibition of human CCF-STTG1 cell growth in a cell viability assay, IC50=1.42525 μM | ||||
| human MC116 cell | Growth inhibition assay | Inhibition of human MC116 cell growth in a cell viability assay, IC50=1.46122 μM | ||||
| human MDA-MB-468 cell | Growth inhibition assay | Inhibition of human MDA-MB-468 cell growth in a cell viability assay, IC50=1.53736 μM | ||||
| human NB12 cell | Growth inhibition assay | Inhibition of human NB12 cell growth in a cell viability assay, IC50=1.54842 μM | ||||
| human LXF-289 cell | Growth inhibition assay | Inhibition of human LXF-289 cell growth in a cell viability assay, IC50=1.55104 μM | ||||
| human MFE-296 cell | Growth inhibition assay | Inhibition of human MFE-296 cell growth in a cell viability assay, IC50=1.56836 μM | ||||
| human SNU-423 cell | Growth inhibition assay | Inhibition of human SNU-423 cell growth in a cell viability assay, IC50=1.57192 μM | ||||
| human NCI-H2291 cell | Growth inhibition assay | Inhibition of human NCI-H2291 cell growth in a cell viability assay, IC50=1.5761 μM | ||||
| human OCUB-M cell | Growth inhibition assay | Inhibition of human OCUB-M cell growth in a cell viability assay, IC50=1.58314 μM | ||||
| human KU812 cell | Growth inhibition assay | Inhibition of human KU812 cell growth in a cell viability assay, IC50=1.59628 μM | ||||
| human HuO9 cell | Growth inhibition assay | Inhibition of human HuO9 cell growth in a cell viability assay, IC50=1.6128 μM | ||||
| human 639-V cell | Growth inhibition assay | Inhibition of human 639-V cell growth in a cell viability assay, IC50=1.63144 μM | ||||
| human HCC70 cell | Growth inhibition assay | Inhibition of human HCC70 cell growth in a cell viability assay, IC50=1.66146 μM | ||||
| human SNB75 cell | Growth inhibition assay | Inhibition of human SNB75 cell growth in a cell viability assay, IC50=1.66508 μM | ||||
| human D-336MG cell | Growth inhibition assay | Inhibition of human D-336MG cell growth in a cell viability assay, IC50=1.6688 μM | ||||
| human LoVo cell | Growth inhibition assay | Inhibition of human LoVo cell growth in a cell viability assay, IC50=1.73825 μM | ||||
| human EB2 cell | Growth inhibition assay | Inhibition of human EB2 cell growth in a cell viability assay, IC50=1.75019 μM | ||||
| human HSC-2 cell | Growth inhibition assay | Inhibition of human HSC-2 cell growth in a cell viability assay, IC50=1.75727 μM | ||||
| human D-542MG cell | Growth inhibition assay | Inhibition of human D-542MG cell growth in a cell viability assay, IC50=1.85077 μM | ||||
| human COLO-684 cell | Growth inhibition assay | Inhibition of human COLO-684 cell growth in a cell viability assay, IC50=2.20032 μM | ||||
| human GDM-1 cell | Growth inhibition assay | Inhibition of human GDM-1 cell growth in a cell viability assay, IC50=2.24206 μM | ||||
| human SW1088 cell | Growth inhibition assay | Inhibition of human SW1088 cell growth in a cell viability assay, IC50=2.48143 μM | ||||
| human SF295 cell | Growth inhibition assay | Inhibition of human SF295 cell growth in a cell viability assay, IC50=2.76955 μM | ||||
| human NCI-H2030 cell | Growth inhibition assay | Inhibition of human NCI-H2030 cell growth in a cell viability assay, IC50=2.90288 μM | ||||
| human NCI-H1755 cell | Growth inhibition assay | Inhibition of human NCI-H1755 cell growth in a cell viability assay, IC50=3.27063 μM | ||||
| human MDA-MB-361 cell | Growth inhibition assay | Inhibition of human MDA-MB-361 cell growth in a cell viability assay, IC50=3.52709 μM | ||||
| Klik om meer experimentele gegevens over cellijnen te bekijken | ||||||
| Molecuulgewicht | 408.45 | Formule | C22H24N4O4 |
Opslag (vanaf de datum van ontvangst) | |
|---|---|---|---|---|---|
| CAS-nr. | 1173900-33-8 | SDF downloaden | Opslag van stamoplossingen |
|
|
| Synoniemen | KIN-193 | Smiles | CC1=CN2C(=O)C=C(N=C2C(=C1)C(C)NC3=CC=CC=C3C(=O)O)N4CCOCC4 | ||
|
In vitro |
DMSO
: 82 mg/mL
(200.75 mM)
Ethanol : 10 mg/mL Water : Insoluble |
|
In vivo |
|||||
Stap 1: Voer onderstaande informatie in (Aanbevolen: een extra dier om rekening te houden met verlies tijdens het experiment)
Stap 2: Voer de in vivo formulering in (Dit is alleen de calculator, geen formulering. Neem eerst contact met ons op als er geen in vivo formulering is in de sectie oplosbaarheid.)
Berekeningsresultaten:
Werkconcentratie: mg/ml;
Methode voor het bereiden van DMSO-moedervloeistof: mg geneesmiddel vooropgelost in μL DMSO ( Concentratie moedervloeistof mg/mL, Neem eerst contact met ons op als de concentratie de DMSO-oplosbaarheid van de batch van het geneesmiddel overschrijdt. )
Methode voor het bereiden van in vivo formulering: Neem μL DMSO moedervloeistof, voeg daarna toeμL PEG300, mengen en verhelderen, daarna toevoegenμL Tween 80, mengen en verhelderen, daarna toevoegen μL ddH2O, mengen en verhelderen.
Methode voor het bereiden van in vivo formulering: Neem μL DMSO moedervloeistof, voeg daarna toe μL Maïsolie, mengen en verhelderen.
Opmerking: 1. Zorg ervoor dat de vloeistof helder is voordat u het volgende oplosmiddel toevoegt.
2. Zorg ervoor dat u het/de oplosmiddel(en) in de juiste volgorde toevoegt. U moet ervoor zorgen dat de verkregen oplossing, bij de vorige toevoeging, een heldere oplossing is voordat u verdergaat met het toevoegen van het volgende oplosmiddel. Fysieke methoden zoals vortexen, ultrasoon of een warmwaterbad kunnen worden gebruikt om het oplossen te bevorderen.
| Targets/IC50/Ki |
PI3Kβ
(Cell-free assay) 10 nM
PI3Kδ
(Cell-free assay) 80 nM
DNA-PK
(Cell-free assay) 420 nM
PI3Kα
(Cell-free assay) 870 nM
|
|---|---|
| In vitro |
AZD6482 remt ook PI3Kα, γ en δ, met een IC50 van 80 nM tot 1,09 μM, welke significant lager zijn dan die van zijn (+)-enantiomeer (S-vorm). Deze verbinding is een antiplaatjesmiddel; het blokkeert plaatjesactivering, adhesie/aggregatie en bevordert plaatjesdisaggregatie in een assay van gewassen plaatjesaggregatie (WPA), met een IC50-waarde van 6 nM. Bovendien remt deze chemische stof, door zich te richten op PI3Kβ, specifiek trombose zonder de normale hemostase te verstoren. Daarom wordt het gebruikt als een antitrombotisch geneesmiddel voor de profylaxe van trombotische aandoeningen.
|
| Kinase Assay |
Assay voor PI3K-enzymremming
|
|
De remming van PI3Kβ, PI3Kα, PI3Kγ en PI3Kδ wordt geëvalueerd in een AlphaScreen-gebaseerde enzymactiviteitsassay met behulp van humane recombinante enzymen. De assay meet de PI3K-gemedieerde omzetting van PIP2 naar PIP3. Gebiotinyleerd PIP3, een GST-gelabeld pleckstrinehomologie (PH)-domein en de twee AlphaScreen-kralen vormen een complex dat een signaal afgeeft bij laserstimulatie op 680 nm. Het PIP3 dat in de enzymreactie wordt gevormd, concurreert met het gebiotinyleerde PIP3 om binding aan het PH-domein, waardoor het signaal afneemt met toenemende enzymproductie. Deze verbinding wordt opgelost in DMSO en toegevoegd aan 384-wells platen. PBKβ, PBKα, PBKγ of PBKδ wordt toegevoegd in een Tris-buffer (50 mM Tris pH 7,6, 0,05% CHAPS, 5 mM DTT en 24 mM MgCl2) en 20 minuten voorafgaand aan de toevoeging van substraatoplossing die PIP2 en ATP bevat, met deze chemische stof geïncubeerd. De enzymreactie wordt na 20 minuten gestopt door toevoeging van een stopoplossing die EDTA en biotine-PIP3 bevat, gevolgd door toevoeging van een detectieoplossing die GST-grpl PH en AlphaScreen-kralen bevat. Platen worden minimaal 5 uur in het donker gelaten voorafgaand aan analyse. De uiteindelijke concentraties van DMSO, ATP en PIP2 in de assay zijn respectievelijk 0,8%, 4 μM en 40 μM. IC50-waarden worden berekend volgens de vergelijking, y = {a+[(b-a)/(l+(x/IC50)s)]}, waarbij y = % remming; a = 0%; b = 100%; s = de helling van de concentratie-responscurve; x = de concentratie van deze verbinding.
|
Referenties |
Tel: +1-832-582-8158 Ext:3
Als u nog andere vragen heeft, laat dan een bericht achter.